Immunovant Inc’s recent filing unveils that its Chief Technology Officer Stout Jay S unloaded Company’s shares for reported $51780.0 on Jan 22 ’25. In the deal valued at $23.59 per share,2,195 shares were sold. As a result of this transaction, Stout Jay S now holds 139,991 shares worth roughly $3.14 million.
Then, Geffner Michael sold 2,657 shares, generating $62,679 in total proceeds. Upon selling the shares at $23.59, the Chief Medical Officer now owns 132,314 shares.
Before that, Macias William L. sold 2,383 shares. Immunovant Inc shares valued at $56,782 were divested by the Chief Medical Officer at a price of $23.83 per share. As a result of the transaction, Macias William L. now holds 359,408 shares, worth roughly $8.05 million.
Wolfe Research downgraded its Immunovant Inc [IMVT] rating to a Peer perform from a an Outperform in a research note published recently. Oppenheimer also remained covering IMVT and reiterated its “an Outperform” recommendation on October 09, 2024. Oppenheimer started covering the stock on March 28, 2024. It rated IMVT as “an Outperform”.
Price Performance Review of IMVT
On Monday, Immunovant Inc [NASDAQ:IMVT] saw its stock fall -2.82% to $22.40. Over the last five days, the stock has lost -6.12%. Immunovant Inc shares have fallen nearly -9.57% since the year began. Nevertheless, the stocks have fallen -42.03% over the past one year. While a 52-week high of $39.55 was reached on 01/02/25, a 52-week low of $22.41 was recorded on 01/27/25. SMA at 50 days reached $26.02, while 200 days put it at $28.29.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 21.93, which if violated will result in even more drops to 21.45. On the upside, there is a resistance level at 23.23. A further resistance level may holdings at 24.06. The Relative Strength Index (RSI) on the 14-day chart is 33.58, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.54%. Stochastics %K at 17.58% indicates the stock is a buying.
How much short interest is there in Immunovant Inc?
A steep rise in short interest was recorded in Immunovant Inc stocks on 2024-12-31, dropping by -0.4 million shares to a total of 12.26 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 12.67 million shares. There was a decline of -3.3%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 13, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
